Chelsea Therapeutics to Present at the Piper Jaffray 23rd Annual Healthcare ... - MarketWatch (press release)

CHARLOTTE, N.C., Nov 29, 2011 (GlobeNewswire via COMTEX) -- Chelsea Therapeutics International, Ltd. /quotes/zigman/97770/quotes/nls/chtp CHTP +5.52% is scheduled to present at the Piper Jaffray 23rd Annual Healthcare Conference at 11:30 AM ET on November 30, 2011 at New York Palace Hotel.

Dr. Simon Pedder, Chelsea's Chief Executive Officer, will provide a brief overview of the company's product pipeline, clinical development status, as well as the FDA's recent acceptance for filing and designation of priority review of its new drug application (NDA) for NORTHERA(TM) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure (Parkinson's disease, multiple system atrophy and pure autonomic failure), dopamine beta hydroxylase deficiency and non-diabetic autonomic neuropathy.

Dr. Pedder's presentation will be webcast live and archived for 90 days on Chelsea's website, .

About Chelsea Therapeutics

Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases. Chelsea's most advanced drug candidate, NORTHERA(TM) (droxidopa), is an orally active synthetic precursor of norepinephrine initially being developed for the treatment of neurogenic orthostatic hypotension. In addition to Droxidopa, Chelsea is also developing a portfolio of metabolically inert oral antifolate molecules engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders, including two clinical stage product candidates: CH-1504 and CH-4051. Preclinical and clinical data suggest superior safety and tolerability, as well as increased potency versus methotrexate (MTX).

This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include risk of regulatory approvals; risks and costs of drug development, including the uncertainty of cost, timing and outcome of clinical trials; our need to raise operating capital; our reliance on our lead drug candidates droxidopa and CH-4051; our history of losses; reliance on collaborations and licenses; intellectual property risks; competition; market acceptance for our products, if any are approved for marketing; and reliance on key personnel including specifically Dr. Pedder.

This news release was distributed by GlobeNewswire,

SOURCE: Chelsea Therapeutics

              CONTACT: Investors:          Kathryn McNeil          Chelsea Therapeutics          704-973-4231          Media:          Lauren Tortorete          Hill & Knowlton          212-885-0348                

(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.


Volume: 288,104

Nov. 28, 2011 4:00p

29 Nov, 2011

Manage subscription | Powered by

What's on Your Mind...

Powered by Blogger.